Drugdiscovery >> Pharmaceutical Companies >> News
3734
Views
New Drug Applications of Gilead was Accepted by FDA - drugdiscovery.com
New Drug Applications of Gilead was Accepted by FDA - drugdiscovery.com


Gilead has announced that its new drug application was accepted by FDA. The new drug is going to be a novel HIV treatment.
Read More >>


Tags: drug, drug development, FDA, HIV drug, Gilead, aids drug - April 24, 2014
Related Articles
3797
Views
GlaxoSmithKline and MD Anderson entered a cancer-drug alliance GlaxoSmithKline and MD Anderson entered a cancer-drug alliance
Anderson Cancer Center of Texas University and GlaxoSmithKline announced that they are going to co-operate in further cancer research. The research for immunotherapy is going to be the part of MD Ande Read More >>

Tags: MD Anderson’s Moon Shots Program, Moon Shots program, drug cancer, immunotherapy, drug research, drug development, pharmaceutical companies, GlaxoSmithKline

5197
Views
 The most efficient drug developers in Big Pharma world The most efficient drug developers in Big Pharma world
Matthew Herper from Forbes investigates which are the most efficient drug developers in biopharma. Read More >>

Tags: drug developers, best, most efficent, biopharma

3012
Views
MMV and Merck Serono are ciollaborating on findig anti malaria drug MMV and Merck Serono are ciollaborating on findig anti malaria drug
MMC and Marck Serono set up a group which is working on a chemical series that has shown significant antimalarial potential. The series has a unique profile as the compounds are long-acting and have d Read More >>

Tags: in vitro, malaria drug, Merck, MMV, malaaria

3536
Views
State of the art of the Pharmaceutical Industry State of the art of the Pharmaceutical Industry
In the United States alone, more than $100 billion is spent annually on pharmaceutical research and development. The pharmaceutical industry has a higher level of expenditures than any other manufactu Read More >>

Tags: drug discovery, pharmaceutical industry, drugs, drug development, clinical trials

1967
Views
Eli Lilly's lung cancer drug is protected by the court Eli Lilly's lung cancer drug is protected by the court
federal court decided to protect Lilly's experimental cacer drug from its generic version.The drug is going to be protected till 2022. Read More >>

Tags: drug; discovery; development; patent protection; Eli Lilly; Alimta; lung cancer

3112
Views
Rockwell’s anemia drug successful in a second late-stage clinical trial Rockwell’s anemia drug successful in a second late-stage clinical trial
Rockwell Medical reported successful results of its experimental anemia drug - SFP, or soluble ferric phosphate, in a second late-stage clinical trial. Small, frequent doses of SFP proved to be safer Read More >>

Tags: Rockwell Medical, rockwell, anemia drug, SFP, soluble ferric phosphate, clinical trial, shares

3438
Views
Obesity drug kills Vivus? Obesity drug kills Vivus?
Qsyma, the anti-obesity drug of Vivus is falling. The company is in crisis. It has lot almost one half of its staff and even one of its CFOs is considering moving. Read More >>

Tags: Vivus, obesity, drug, crisis

5511
Views
Isis shares climbe after positive results from its spinal muscular atrophy drug study Isis shares climbe after positive results from its spinal muscular atrophy drug study
Isis Pharmaceuticals drug designed to treat spinal muscular atrophy showed success in a mid- stage study. This announcement led to a raise of company’s shares. Read More >>

Tags: news, Isis Pharmaceutical, spinal muscular atrophy, clinical trial, shares, experimental drug

2688
Views
Chinese drug developer Simcere goes private Chinese drug developer Simcere goes private
Simcere Pharmaceutical Group, focused on the treatment of diseases that have high incidence or mortality rates, plans to go private in a deal with a buyout group led by founder Jinsheng Ren. The deal Read More >>

Tags: Simcere Pharmaceutical Group, simcere, China, drug developer, chinese

4115
Views
Novartis has named the new leaders of Alcon and Sandoz Novartis has named the new leaders of Alcon and Sandoz
These new leaders will set the direction for the next phase of growth for our eye care and generics businesses, two of our core growth engines. Read More >>

Tags: biosimilars, pharmaceutical business, pharma leaders, novartis, alcon, sandoz, drug, drug ceo, Chutes and Ladders, Novartis, Sandoz,

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013